Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James K Sheffield

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trialRobert T Naismith, Jeffrey A Cohen, Amit Bar-Or, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGiancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2022
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialBruce Ac Cree, Krzysztof W Selmaj, Lawrence Steinman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2025
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trialsJeffrey A Cohen, Douglas L Arnold, John DeLuca, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2025
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trialKrzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trialRobert T Naismith, Jeffrey A Cohen, Amit Bar-Or, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGiancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2022
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialBruce Ac Cree, Krzysztof W Selmaj, Lawrence Steinman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 23, 2025
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trialsJeffrey A Cohen, Douglas L Arnold, John DeLuca, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2025
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trialKrzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, et al.
Pageof 2